


AMENDMENTS

Kindly amend the subject application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula:



wherein:

P is a water soluble polymer;

m is an integer from 2-12 inclusive;

j is an integer from 1-6 inclusive;

Application Serial No.: 10/506,524

R_i is a group selected from the group consisting of H, C_{1-12} alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group;

Z is a linking group selected from O and NH; and

TA is a drug molecule.

2. (Previously presented) The conjugate of claim 1, wherein the water soluble polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyacrylmorpholine and copolymers thereof.


3. (Previously presented) The conjugate of claim 2, wherein the water soluble polymer is polyethylene glycol.

4. (Previously presented) The conjugate of claim 3, wherein the molecular weight of polyethylene glycol is from 300 to 60,000.

5. (Previously presented) The conjugate of claim 1, wherein the linking group X is selected from the group consisting of $(CH_2)_i$, $(CH_2)_iOCO$, $(CH_2)_iNHCO$ and $(CH_2)_iCO$, and wherein i is an integer from 0-10, inclusive.

6. (Previously presented) The conjugate of claim 1, wherein a free hydroxyl on the hydrophilic polymer can be substituted by C_{1-12} alkoxy, cycloalkoxy or aroxy.

7. (Currently amended) The conjugate of claim 1, wherein a free hydroxyl on the hydrophilic polymer is substituted by the following formula:



wherein:

~~P is a water soluble polymer;~~

m is an integer from 2-12 inclusive;

j is an integer from 1-6 inclusive;

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group;

Z is a linking group selected from O and NH; and

TA is a drug molecule.

8. (Previously presented) The conjugate of claim 1, wherein target molecule can be carried in the hydrophilic polymer to perform targeted delivery of the conjugate.

9. (Previously presented) The conjugate of claim 8, wherein the target molecule is an antibody.

10. (Previously presented) The conjugate of claim 1, wherein the drug molecule TA is selected from the group consisting of amino acids, proteins, enzymes,

Application Serial No.: 10/506,524

nucleosides, saccharides, organic acids, glycosides, flavonoids, quinones, terpenoids, phenylpropanoid phenols, steroids and glycosides thereof and alkaloids.


11. (Previously presented) The conjugate of claim 10, wherein the drug molecule TA is an active ingredient of a nature medicine.

12. (Withdrawn) The conjugate of claim 11, wherein the active ingredient is cinobufagin, clycyrrhetic acid or scopoletin.

13. (Previously presented) The conjugate of claim 10, wherein the drug molecule TA is an antitumor agent.

14. (Currently amended) The conjugate of claim 13, wherein the antitumor agent is selected from the group consisting of paclitaxel, camptothecin, hydroxylcamptothecin, etoposide and ~~derivatives~~ esters thereof.

15. (Currently amended) A conjugate of methoxypolyethylene glycol-glutamic acid oligopeptide and drug molecule having the following formula:



Application Serial No.: 10/506,524

wherein:

n is an integer from 10-1200;

m is an integer from 2-12;

X is a linking group selected from the group consisting of $(\text{CH}_2)_i$, $(\text{CH}_2)_i\text{OCO}$, $(\text{CH}_2)_i\text{NHCO}$ and $(\text{CH}_2)_i\text{CO}$, and wherein i is an integer from 0-10 inclusive;

Z is a linking group selected from O and NH; and

PT is a drug molecule selected from the group consisting of paclitaxel, camptothecin, cinobufagin, clycyrrhetic acid, scopoletin and derivatives esters thereof.

16. (Previously presented) A composition comprising a conjugate according to claim 1 and a pharmaceutically acceptable carrier or excipient.

17. (Previously presented) The composition of claim 16, further comprising another therapeutically active ingredient.

18. (Previously presented) The composition of claim 16, wherein the composition is formulated into a form selected from the group consisting of a tablet, a suppository, a pill, a soft gelatin capsule, a hard gelatin capsule, a powder, a solution, a suspension, and an aerosol.

19. (Canceled)

20. (Previously presented) A composition comprising a conjugate according to claim 15 and a pharmaceutically acceptable carrier or excipient.

21. (Previously presented) The composition of claim 20, further comprising another therapeutically active ingredient.

Application Serial No.: 10/506,524

22. (Previously presented) The composition of claim 20, wherein the composition is formulated into a form selected from the group consisting of a tablet, a suppository, a pill, a soft gelatin capsule, a hard gelatin capsule, a powder, a solution, a suspension, and an aerosol.